LEIDOS BIOMEDICAL RESEARCH INC

Federal contract award, Leidos, $5,872,547

Key CONT_AWD_75N91023F00017_7529_75N91019D00024_7529. First seen by this system September 5, 2026 through the historical sweep, new to the watchlist, public 348 days before this system saw it. One version on record.

Cite this row

On this site https://evidence.ourrevolution.media/filings/leidos/CONT_AWD_75N91023F00017_7529_75N91019D00024_7529

At the source https://www.usaspending.gov/award/CONT_AWD_75N91023F00017_7529_75N91019D00024_7529

Observed 2026-09-05, version 1, retrieved 2026-09-05T00:55:20Z

Content hash e06b49dfb0561a6d5439bc86b20434186d3e66e9cbce394092f23a4413080ac5

The source record can change after this date; the key, hash and retrieval time name exactly the response this system stored. See license and citation.

Versions

Version	Amount	Change	Occurred	Published	Retrieved	How it arrived	Content hash
1 current	$5,872,547	first version	September 13, 2023	September 22, 2025	2026-09-05T00:55:20Z	historical sweep	`e06b49dfb056`

Archived copy

https://web.archive.org/web/20261014070539/https://www.usaspending.gov/award/CONT_AWD_75N91023F00017_7529_75N91019D00024_7529 captured by this system, October 14, 2026

What the amount is made of

3 recorded actions, so the amount is the award's current total across all of them. 3 of them obligated money. Measured 2026-10-11, when USAspending reported a total obligation of $5,872,547.

Action date	Modification	Type	Obligated	Description as recorded
September 22, 2025	P00002	EXERCISE AN OPTION	+$560,278	THE NIAID MISSION AND SCOPE INCLUDING RESEARCH AND DEVELOPMENT OF VACCINES AND THERAPEUTICS FOR THE PREVENTION AND TREATMENT OF DISEASES OF HUMAN CONCERN, INCLUDING MALARIA. THE VACCINE RESEARCH CENTER (VRC) HAS DEVELOPED TWO MONOCLONAL ANTIBODIES (M
July 14, 2025	P00001	EXERCISE AN OPTION	+$651,914	THE NIAID MISSION AND SCOPE INCLUDING RESEARCH AND DEVELOPMENT OF VACCINES AND THERAPEUTICS FOR THE PREVENTION AND TREATMENT OF DISEASES OF HUMAN CONCERN, INCLUDING MALARIA. THE VACCINE RESEARCH CENTER (VRC) HAS DEVELOPED TWO MONOCLONAL ANTIBODIES (M
September 13, 2023	base	not on file	+$4,660,355	THE NIAID MISSION AND SCOPE INCLUDING RESEARCH AND DEVELOPMENT OF VACCINES AND THERAPEUTICS FOR THE PREVENTION AND TREATMENT OF DISEASES OF HUMAN CONCERN, INCLUDING MALARIA. THE VACCINE RESEARCH CENTER (VRC) HAS DEVELOPED TWO MONOCLONAL ANTIBODIES (M

Last refreshed November 4, 2026 at 2:31 PM UTC.